Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 613

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 2
Chunk 613
---
 units 
     29,997  
     —  
     —  
     —  
     — 
  
    Issuance of common stock, warrants, and pre-funded warrants, net of issuance fees of $740,477 
     395,574  
     4  
     3,590,406  
     —  
     3,590,410 
  
    Common stock issued for the exercise of pre-funded warrants 
     729,246  
     8  
     722  
     —  
     730 
  
    Stock-based compensation 
     —  
     —  
     259,744  
     —  
     259,744 
  
    Net loss 
     —  
     —  
     —  
     (9,144,797) 
     (9,144,797)
  
    Balance at December 31, 2024 
     4,076,567  
    $41  
    $35,287,212  
    $(34,578,101) 
    $709,152 
  
    Balance at December 31, 2024 
     4,076,567  
    $41  
    $35,287,212  
    $(34,578,101) 
    $709,152 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Cash Flows

    2024  
    2023 

    Years Ended

    December 31,

    2024  
    2023 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(9,144,797) 
    $(6,592,723)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     5,463  
     6,811 
  
    Change in fair value of derivative liabilities 
     (555,789) 
     (2,216,488)
  
    Amortization of debt discount and finance fees 
     1,079,444  
     2,123,049 
  
    Gain on marketable securities